Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Rituximab in Previously Untreated CLL/SLL
NCT04458610Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2020
- Primary completion
- May 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2020; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04458610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458610.